Results 21 to 30 of about 141,357 (291)

Dramatic Deep and Durable Remission of Acute Fulminant Ulcerative Colitis Achieved with Cyclosporine in a Patient Who Failed the Induction Intravenous Phase of Cyclosporine

Case Reports in Gastroenterology, 2021
Medical rescue therapy for patients with severe steroid-refractory ulcerative colitis (UC) consists of intravenous (IV) cyclosporine or infliximab and remains limited.
Alicia Philippou, Anam Rizvi, Adam Steinlauf   +2 more
doaj   +1 more source

The use of FK-506 for small intestine llotransplantation: Inhibition of acute rejection and prevention of fatal graft-versus-host disease [PDF]

, 1990
Small intestine allotransplantation in humans is not yet feasible due to the failure of the current methods of immunosuppression. FK-506, a powerful new immunosuppressive agent that is synergistic with cyclosporine, allows long-term survival of ...
Banner, B, Cai, X, Cramer, DV, Hoffman, AL, Makowka, L, Pascualone, A, Starzl, TE, Todo, S   +7 more
core   +1 more source

Vasospasm is a significant factor in cyclosporine-induced neurotoxicity: Case report

BMC Neurology, 2010
Background The aetiology of central nervous system lesions observed in cerebral cyclosporine neurotoxicity remains controversial. Case presentation We report a 48-year-old woman with a non-severe aplastic anaemia who presented with stroke-like episodes ...
Span Lambert FR, Postma Alida A, Lodder Jan, Braakman Hilde MH, Mess Werner H   +4 more
doaj   +1 more source

Cyclosporine protects from intestinal epithelial injury by modulating butyrate uptake via upregulation of membrane monocarboxylate transporter 1 levels

Biochemistry and Biophysics Reports, 2020
Background and aims: A relationship between treatment outcomes and intestinal microbiota in patients with inflammatory bowel diseases has been demonstrated. Cyclosporine treatment leads to rapid improvement in severe ulcerative colitis.
Shinji Ota, Hirotake Sakuraba, Hiroto Hiraga, Shukuko Yoshida, Miwa Satake, Yui Akemoto, Nahoko Tanaka, Rina Watanabe, Maeda Takato, Yasuhisa Murai, Kayo Ueno, Takenori Niioka, Makoto Hayakari, Yoh Ishiguro, Shinsaku Fukuda   +14 more
doaj   +1 more source

Oral administration of ginseng ameliorates cyclosporine-induced pancreatic injury in an experimental mouse model. [PDF]

PLoS ONE, 2013
BACKGROUND: This study was performed to investigate whether ginseng has a protective effect in an experimental mouse model of cyclosporine-induced pancreatic injury.
Sun Woo Lim, Kyoung Chan Doh, Long Jin, Shang Guo Piao, Seong Beom Heo, Yu Fen Zheng, Soo Kyung Bae, Byung Ha Chung, Chul Woo Yang   +8 more
doaj   +1 more source

Case report: Cyclosporine A-induced extrapyramidal syndrome following hematopoietic stem cell transplantation

Frontiers in Neurology, 2023
IntroductionCyclosporine A-associated neurotoxicity has been reported in up to 40% of patients and its wide range of neurological adverse effects have been reported, ranging from mild tremors to fatal leukoencephalopathy.
Fatema Al-Amrani, Abdulhakeem Al Rawas, Eiman Al-Ajmi, Amna Al Futaisi   +3 more
doaj   +1 more source

Pure White Cell Aplasia and Immune Thrombocytopenia after Thymoma Resection: A Case Report and Review of the Literature

Case Reports in Hematology, 2022
We report a case of pure white cell aplasia (PWCA) postthymoma resection in a 74-year-old male presenting with a 2-week history of fevers, night sweats, and severe febrile neutropenia.
Michael Youssef, Tyler W. Stratton, Reid C. Gallant, Christine Young, Daniel Y. Li, Siavash Piran   +5 more
doaj   +1 more source

Cyclosporine

Turkderm Turkish Archives of Dermatology and Venereology, 2022
Cyclosporine is an immunosuppressive agent used in the treatment of psoriasis. It shows its action through calcineurin inhibition and T-lymphocytes.
Nahide Onsun
doaj   +1 more source

Cyclosporine for omalizumab-refractory chronic urticaria: a report of five cases

Allergy, Asthma & Clinical Immunology, 2023
Background While both the AAAAI/ACAAI and the EAACI/GA2LEN/EuroGuiDerm/APAAACI guidelines recommend starting cyclosporine for patients with chronic urticaria who have had an inadequate response to omalizumab, many clinicians are hesitant to initiate ...
Anthony F. LaCava, Olajumoke O. Fadugba
doaj   +1 more source

Changes in the blood cyclosporine level after switching from voriconazole to isavuconazole in a patient with aplastic anemia: insights from physiologically based pharmacokinetic model simulation and the Adverse Event Reporting System database study

Frontiers in Microbiology
IntroductionIsavuconazole, a broad-spectrum triazole approved by the United States Food and Drug Administration (FDA) in 2015, moderately inhibits cytochrome P450 3A4.
Chihiro Shiraishi, Chihiro Shiraishi, Hideo Kato, Hideo Kato, Kazuko Ino, Takuya Iwamoto, Takuya Iwamoto   +6 more
doaj   +1 more source